Timothy J Brown

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4714467/publications.pdf

Version: 2024-02-01

54 1,770 12
papers citations h-index

54 54 54 4350 all docs docs citations times ranked citing authors

288905

40

g-index

#	Article	IF	CITATIONS
1	Association of the Extent of Resection With Survival in Glioblastoma. JAMA Oncology, 2016, 2, 1460.	3.4	710
2	Next-Generation Sequencing Directs Therapy and Delineates a Clonal Relationship in Mast Cell Sarcoma and Acute Myeloid Leukemia. JCO Precision Oncology, 2019, 3, 1-6.	1.5	429
3	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood, 2017, 129, e26-e37.	0.6	195
4	Metabolic changes during ovarian cancer progression as targets for sphingosine treatment. Experimental Cell Research, 2013, 319, 1431-1442.	1.2	54
5	Management of low-grade glioma: a systematic review and meta-analysis. Neuro-Oncology Practice, 2019, 6, 249-258.	1.0	52
6	Management of Cancer Therapy–Associated Oral Mucositis. JCO Oncology Practice, 2020, 16, 103-109.	1.4	48
7	Chemotherapy-Induced Peripheral Neuropathy. JAMA Oncology, 2019, 5, 750.	3.4	42
8	Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 270-274.	0.6	25
9	Patient-Specific Instrumentation Does Not Improve Alignment in Total Knee Arthroplasty. Journal of Knee Surgery, 2014, 27, 501-504.	0.9	24
10	Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. Blood Advances, 2019, 3, 2598-2603.	2.5	24
11	Pasireotide for the treatment of refractory hypoglycaemia from malignant insulinoma. Clinical Endocrinology, 2018, 88, 341-343.	1.2	22
12	PARP Inhibitors in Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 465-475.	1.0	18
13	Magic Mouthwash for Oral Mucositis. JAMA Internal Medicine, 2019, 179, 104.	2.6	13
14	Reducing Hospitalizations: Institution of Outpatient Infusional EPOCH-Based Chemotherapy at a Safety Net Hospital. Journal of Oncology Practice, 2019, 15, e644-e651.	2.5	11
15	Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab. Head and Neck, 2017, 39, E69-E71.	0.9	8
16	Therapeutic effect of <scp>Northern Labrador</scp> tea extracts for acute myeloid leukemia. Phytotherapy Research, 2018, 32, 1636-1641.	2.8	7
17	Applying the 'COST' (Culture, Oversight, Systems Change, and Training) Framework to De-Adopt the Neutropenic Diet. American Journal of Medicine, 2019, 132, 42-47.	0.6	7
18	Rates of appropriate laxative prophylaxis for opioid-induced constipation in veterans with lung cancer: a retrospective cohort study. Supportive Care in Cancer, 2020, 28, 5315-5321.	1.0	7

#	Article	IF	CITATIONS
19	Improving the Time to Activation of New Clinical Trials at a National Cancer Institute–Designated Comprehensive Cancer Center. JCO Oncology Practice, 2020, 16, e324-e332.	1.4	7
20	Immunotherapy Adverse Effects. JAMA Oncology, 2021, 7, 1908.	3.4	7
21	Dissemination of Information on Neutropenic Diet by Top US Cancer Centers: In-line with the Evidence?. Nutrition and Cancer, 2019, 71, 1272-1275.	0.9	5
22	Palliative Care. JAMA Oncology, 2019, 5, 126.	3.4	5
23	Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation. ACG Case Reports Journal, 2017, 4, e48.	0.2	5
24	Therapeutic Effect of Blueberry Extracts for Acute Myeloid Leukemia., 2018, 1,.		5
25	Importance of addressing malnutrition in cancer and implementation of a quality improvement project in a gastrointestinal cancer clinic. Nutrition in Clinical Practice, 2022, 37, 215-223.	1.1	4
26	Epigenetics and Sphingolipid Metabolism in Health and Disease. International Journal of Biopharmaceutical Sciences, 2018, 1 , .	0.5	4
27	Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials. Gastrointestinal Tumors, 2022, 9, 19-26.	0.3	4
28	Large saddle embolus during cancer therapy. BMJ Case Reports, 2016, 2016, bcr2016215837.	0.2	3
29	Extent of Resection and Survival in Glioblastoma Multiforme—Reply. JAMA Oncology, 2016, 2, 1509.	3.4	3
30	Decreasing Inappropriate Use of Rasburicase to Promote Cost-Effective Care. Journal of Oncology Practice, 2019, 15, e178-e186.	2.5	3
31	Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia. , 2018, 1, \cdot		3
32	Lessons from spending on megestrol for cancer cachexia. Supportive Care in Cancer, 2021, 29, 5553-5555.	1.0	2
33	Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer Journal of Clinical Oncology, 2021, 39, e15580-e15580.	0.8	2
34	Development of a nutrition-focused quality improvement program for new patients with cancer seen at the UTSW Simmons Comprehensive Cancer Center (SCCC) outpatient gastrointestinal (GI) oncology clinic Journal of Clinical Oncology, 2018, 36, 143-143.	0.8	2
35	A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, <i>BRCA-</i> or <i>PALB2-</i> related pancreatic cancer who have progressed on rucaparib Journal of Clinical Oncology, 2022, 40, 4131-4131.	0.8	2
36	Finding the Magic in Magic Mouthwashâ€"Reply. JAMA Internal Medicine, 2019, 179, 724.	2.6	1

#	Article	IF	Citations
37	Myopathy in a 61-year-old Hispanic man. BMJ Case Reports, 2019, 12, e228892.	0.2	1
38	330. Survival of HIV-Positive Patients with Hemophagocytic Lymphohistiocytosis. Open Forum Infectious Diseases, 2019, 6, S175-S176.	0.4	1
39	Trends of clinical outcomes with sorafenib in randomized controlled trials for patients with treatment-na \tilde{A} -ve advanced hepatocellular carcinoma Journal of Clinical Oncology, 2021, 39, 327-327.	0.8	1
40	Examining extent of resection and progression-free survival in glioblastoma: A systematic review and meta-analysis Journal of Clinical Oncology, 2016, 34, e13500-e13500.	0.8	1
41	Association of aggressive resection with survival and progression-free survival in adult low-grade glioma: A systematic review and meta-analysis with numbers needed to treat Journal of Clinical Oncology, 2017, 35, 2025-2025.	0.8	1
42	Overall Survival of HIV-Positive Patients with HLH. Blood, 2018, 132, 4957-4957.	0.6	1
43	Applying quality improvement methodologies to decrease the time-to-activation of new clinical trials at an NCI-designated comprehensive cancer center Journal of Clinical Oncology, 2019, 37, 296-296.	0.8	1
44	A 57-Year-Old Man With Subacute Progressive Hemoptysis and Fevers. Chest, 2018, 154, e181-e185.	0.4	0
45	Promoting High-Value Change by Addressing the Structure of Order Sets: Lessons From the Cardiac Catheterization Lab. American Journal of Medical Quality, 2019, 34, 312-312.	0.2	0
46	A High-Value Care Initiative to Reduce the Use of Intravenous Magnesium Sulfate Through an Electronic Indication-Based Order Set. Joint Commission Journal on Quality and Patient Safety, 2021, 47, 802-808.	0.4	0
47	Enhancing Ceramide Cytotoxicity in Acute Myelogenous Leukemia. Blood, 2012, 120, 4905-4905.	0.6	0
48	Abstract 3396: Improving the anti-AML efficacy of liposomal ceramide by targeting sphingolipid metabolism , $2013, , .$		0
49	Target wise and pound foolish: A simple technique to evaluate the trade-off between economic burden and clinical benefit of monoclonal antibodies Journal of Clinical Oncology, 2015, 33, 6598-6598.	0.8	0
50	Quantifying the benefit of chemotherapy and radiation in low-grade glioma: A systematic review and meta-analysis of numbers needed to treat Journal of Clinical Oncology, 2017, 35, 2057-2057.	0.8	0
51	Effectiveness of biomarker surveillance after treatment in locoregional breast cancer Journal of Clinical Oncology, 2018, 36, e12608-e12608.	0.8	0
52	Association of anticonvulsant prophylaxis in patients with primary and metastatic brain tumors and 1-year overall survival: A systematic review and meta-analysis Journal of Clinical Oncology, 2018, 36, 2043-2043.	0.8	0
53	Saving TIME: Accuracy of a text intervention to minimize the time burden of cancer care Journal of Clinical Oncology, 2022, 40, 6527-6527.	0.8	0
54	Challenges in the Management of Patients With HER2-Amplified Colorectal Cancer. JCO Oncology Practice, 0, , .	1.4	0